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Abstract
Glucocorticoids (GCs) are involved in multiple metabolic processes, including the regulation of insulin sensitivity and
adipogenesis. Their action partly depends on their intracellular activation by 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1). We previously demonstrated that central GC administration promotes hyperphagia, body weight gain,
hyperinsulinemia and marked insulin resistance at the level of skeletal muscles. Similar dysfunctions have been reported to
occur upon specific overexpression of 11b-HSD1 in adipose tissue. The aim of the present study was therefore to determine
whether the effects of central GC infusion may enhance local GC activation in white adipose tissue. Male Wistar and Sprague
Dawley (SD) rats were intracerebroventricularly infused with GCs for 2 to 3 days. Body weight, food intake and metabolic
parameters were measured, and expression of enzymes regulating 11b-HSD1, as well as that of genes regulated by GCs,
were quantified. Central GC administration induced a significant increase in body weight gain and in 11b-HSD1 and resistin
expression in adipose tissue. A decrease 11b-HSD1 expression was noticed in the liver of SD rats, as a partial compensatory
mechanism. Such effects of GCs are centrally elicited. This model of icv dexamethasone infusion thus appears to be a
valuable acute model, that helps delineating the initial metabolic defects occurring in obesity. An impaired downregulation
of intracellular GC activation in adipose tissue may be important for the development of insulin resistance.
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Introduction
Glucocorticoids (GCs) influence a wide variety of physiological
functions, including food intake, body weight and energy metab-
olism [1,2]. Excess of GCs, whether of endogenous origin as in
Cushing’s syndrome [3,4] or genetically obese mice and rats [5,6] is
known to promote obesity, insulin resistance, hyperglycemia, and
dyslipidemia, characterizing the ‘‘metabolic syndrome’’. Although a
state of hypercorticism is often encountered in idiopathic obesity,
circulating cortisol/corticosterone levels can be near normal and
even low [7,8]. These observations do not preclude the presence of
increased local GC activity in obesity/insulin resistance [9,10].
Indeed, intracellular activity of GCs not only depends on their
circulating levels, but also on their tissue-specific metabolism by two
distinct isoforms of 11b-hydroxysteroid dehydrogenase (11b-HSD),
type 1 and type 2 [11,12], and by expression levels of the GC
receptor (GR). 11b-HSD1, expressed in both human and rodent
liver [11], adrenal cortex [13] and adipose tissue [14], acts as a low
affinity (high Km for cortisol/corticosterone) NADP(H)-dependent
reductase, leading to increased GC activation [15]. The importance
of 11b-HSD1 in adipose tissue is suggested by the observation of a
three to four fold increase in 11b-HSD1 reductase activity in
adipose tissue of obese patients [16]. Glucose intolerance and
muscle insulinresistanceareassociated with increased adipose tissue
11b-HSD1 activity in obese humans [17], as well as adipose tissue
insulin resistance in mice [18]. The physiopathological impact of
such an increase has been studied by overexpressing 11b-HSD1
specifically in adipose tissue in mice. Strikingly, these rodents have
developed a phenotype similar to the metabolic syndrome, with
increased central adiposity, impaired glucose tolerance, hypertri-
glyceridemia but normal circulating corticosterone levels [19,20].
Reciprocally, mice lacking 11b-HSD1 are shown to be resistant to
the development of the metabolic syndrome and exhibited
improved glucose tolerance, despite high basal plasma corticoste-
rone levels [10].
On the other hand, 11b-HSD2, mainly expressed in aldoste-
rone-target tissues such as the distal nephron and colon, is a high
affinity 11b-dehydrogenase that catalyzes rapid inactivation of
GCs. Interestingly, 11b-HSD2 was recently reported to be
expressed in adipocytes and the stroma-vascular fraction of
adipose tissue of obese rats and humans [21,22], suggesting that
this enzyme could play an important role in intracellular GC
inactivation and availability for GR in this tissue [23].
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tissue-specific modulation of GC production is a key determinant
of metabolic homeostasis, particularly during periods of enhanced
weight gain and fat deposition. Interestingly, we have previously
showed that infusion of the synthetic GC dexamethasone results in
increased food intake and a rapid body weight gain, hyperinsu-
linemia, hypertriglyceridemia, hyperleptinemia and skeletal mus-
cle insulin resistance upon central, but not peripheral administra-
tion in Sprague Dawley (SD) rats [24,25]. Such deleterious effects
of elevated central GCs are suggested to be mediated by a
concomitant increase in hypothalamic neuropeptide Y (NPY) and
decrease in corticotropin-releasing hormone (CRH) content, in
line with the presence of hypocorticosteronemia due to the
feedback inhibition of the hypothalamo-pituitary-adrenal (HPA)
axis [24,25]. NPY is indeed a potent orexigenic factor that also
affects peripheral metabolism by increasing lipogenic pathways
and promoting muscle insulin resistance. The aim of the present
study was therefore to investigate whether the deleterious
metabolic effects of central dexamethasone infusion also involve
modulation of adipose tissue 11b-HSD type 1 and 2 expression.
This was studied in two different strains of rats, displaying different
susceptibilities to the development of obesity. The gene expression
levels of resistin, an adipocyte-derived factor that impairs insulin
action on glucose metabolism [26,27,28], as well as promotes
dyslipidemia in rodents [29] was also determined. Indeed, it has
been shown that GCs upregulated resistin expression, both in vivo
and in vitro, although this effect might not be exerted directly, via a
glucocorticoid-responsive element [30]. Finally, the central
mediation of adipose tissue 11b-HSD1 expression changes was
assessed by determining the effects of peripherally administered
dexamethasone on metabolic parameters. We showed that central
GC administration induced a significant increase in body weight
gain and 11b-HSD1 and resistin expression in adipose tissue,
while these changes were not observed when dexamethasone was
delivered peripherally. Such centrally elicited effects may thus be
important for the development of insulin resistance.
Methods
Ethics Statement
All procedures were performed in accordance with and
approved by the Institutional Ethical Committee of Animal Care
in Geneva and Cantonal Veterinary Office (experiment ID 1034/
3025/2).
Animals
Male Wistar (200–225 g) and SD (200–225 g) rats were
purchased from Charles River (L’Arbresle, France) and housed
under controlled temperature (23uC) and lighting (light on: 0700–
1900 h). They were allowed free access to water and a standard
laboratory diet (RMI, Hersteller, Essex, UK) (14.7% proteins,
2.6% fat, 68.0% carbohydrates). Body weight and food intake
were recorded in the morning (0830–0930 h).
Intracerebroventricular (icv) infusion of dexamethasone
After one week of acclimatization, rats were individually housed
and submitted to surgical procedures. They were anesthetized with
intramuscular injection of ketamine-xylasine (KetalarH-RompunH,
Figure 1. Food intake, body weight gain, plasma corticosterone, insulin and leptin levels of Wistar rats. Central (icv) dexamethasone
infusion for 3 days. A) Results are expressed as food ingested (in grams) during the last two days of icv infusion. B) Results represent body weight gain
(in grams) measured after 2 and 3 days of icv infusion. C to E) Plasma levels of corticosterone, insulin and leptin. Mean 6 SEM of n=7 rats per group.
*P,0.05 compared to vehicle-infused control rats (Student’s t test and Mann-Whitney test).
doi:10.1371/journal.pone.0034002.g001
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kg, respectively, and implanted with a cannula in the right lateral
cerebral ventricle [31]. After one week of recovery, the drinking
response to icv injection of Angiotensin II (5 ng/ml) (Novabio-
chem, La ¨ufelfingen, Switzerland) was measured to confirm the
correct placement of the cannula. Osmotic minipumps (AlzetH,
model 2001, Alza Corporation, Cupertino, CA) delivering either
the vehicle (0.9% NaCl) or dexamethasone diluted in 0.9% NaCl
(AacidexamH, N.V. Organon, Oss, Netherland) were then
subcutaneously implanted and connected to the icv cannula via a
polyethylene catheter, as previously described [31]. From results
obtained on the body weight (BW) gain, after a pilot dose-response
study (2.5 and 5 mg/day), a dose of 5 mg/day was finally chosen, as
previously published [25]. Wistar rats were treated for 3 days and
SD rats for 2 days to obtain similar body weight gains. Animals
were then sacrificed in the fed state, using isoflurane anesthesia
(Halocarbon Laboratories, River Edge, NJ) and rapid decapitation
between 0900 and 1300 h. Blood samples were collected into
EDTA-coated tubes, centrifuged and plasma stored at 220uC
until use. Tissues were rapidly removed, freeze-clamped, and
stored at 280uC.
Peripheral (sc) infusion of dexamethasone
After one week of adaptation, SD rats were individually housed
and submitted to surgical procedures. They were briefly
anesthetized with isoflurane and osmotic minipumps (AlzetH,
model 1003D) delivering either the vehicle (0.9% NaCl) (control
group, n=8)or5mg/day dexamethasone (n=9) were subcutane-
ously implanted for two days. Rats were sacrificed by isoflurane
anesthesia and rapid decapitation between 0900 and 1200 h.
Blood samples and tissues were collected as described above.
Indirect calorimetry (LabMaster)
Different metabolic parameters, spontaneous activity, as well as
food and drinking behaviors were measured using a 12-cage
LabMaster indirect calorimetry system (TSE Systems GmbH,
Berlin, Germany) of the Small Animal Phenotyping Core facility
(CMU, University of Geneva, Geneva), under controlled tempera-
ture (2261uC) and lighting (12 h light-dark cycle). The calorimetry
system is an open-circuit determining O2 consumption (ml/h/kg),
CO2 production (ml/h/kg), respiratory exchange rate (RE-
R=VCO2/VO2,w h e r eV is volume), and heat produced by the
animal (kcal/h/kg). Detection of animal location and movements is
performed with infraredsensor pairsarrangedinstripsfor horizontal
activity, discriminating between ambulatory and fine movements.
The LabMaster also consists of a combination of highly sensitive
feeding and drinking sensors for automated online measurements.
Before recording, animals were allowed a 14-day acclimatization
period in training cages. Measurements were performed over the
48 h of saline or dexamethasone infusion.
Body composition
An EchoMRI-700 quantitative nuclear magnetic resonance
analyzer (Echo Medical Systems, Houston, TX) was used to
measure total fat and lean body mass at the end of the treatments.
In addition, various white adipose tissue depots (inguinal,
epididymal, perirenal and mesenteric) were carefully dissected
and weighted after sacrifice.
Plasma measurements
Plasma glucose was measured by the glucose oxidase method
(Roche Diagnostics GmbH, Rotkreuz, Switzerland). Plasma
nonesterified fatty acids (NEFA) and triglycerides (TG) were
determined using Wako Chemicals GmbH (Neuss, Germany) and
bioMe ´rieux (Marcy l’Etoile, France) commercial kits, respectively.
Plasma corticosterone (Immunodiagnostic systems Ltd, Boldon,
UK) and leptin (Linco Research Inc., St Charles, MO) levels were
determined using a double antibody RIA with a 3% intra-assay
coefficient of variation, and plasma insulin levels were measured
by RIA, as previously described [32]. In one of the experiments,
plasma corticosterone and 11-dehydrocorticosterone were also
measured by LC-MSMS (Department of Pharmaceutical Sciences,
University of Basel). Plasma dexamethasone levels after icv
treatment in Wistar rats were measured by mass spectrometry
(Centre for Cardiovascular Science, The Queen’s Medical
Research Institute, Edinburgh, UK). Briefly, dexamethasone was
quantified by liquid chromatography tandem mass spectrometry
using as Surveyor HPLC, equipped with a Allure biphenyl column
(5 mm, 10064.6 mm; Thames Restek, Buckinghamshire, UK)
linked to a TSQ Quantum mass spectrometer (Thermo Electron,
Hemel Hempstead, UK) operated in electrospray mode (source
temperature 400uC, spray voltage 3.5 kV, argon pressure 1.5 Pa)
as reported before [33]. Steroids were eluted using a mobile phase
of 60:40 (methanol: ammonium acetate (5 mM), 0.5 ml/min,
30uC) and quantified versus a calibration curve. Mass transitions
monitored were dexamethasone (m/z 393R147), D4-dexameth-
asone (397R377 and R359).
Total adipose tissue lipids and hepatic TG content
For the determination of total lipids in inguinal adipose tissue,
weighed quantities of frozen tissue (<200 mg) were powdered
under liquid N2 and extracted overnight at 4uCi n5 m l
chloroform/methanol (2:1 vol/vol). After filtration, extracts were
added with 1 ml sterile water and centrifuged (3,000 g, 10 min).
They were washed twice by adding 1.5 ml of upper phase washing
Table 1. Effects of dexamethasone treatment on metabolic
parameters.
Controls Dex 5 mg/day
Icv treated Wistar rats
Pre-treatment food intake (g) 22.162.3 22.961.1
Post-treatment body weight (g) 344.661.1 336.565.9
Glucose (mg/L) 143.665.5 146.6610.4
NEFA (mmol/L) 0.2260.08 0.6560.21
TG (mg/dL) 80.3615.8 56.267.7
Icv treated SD rats
Pre-treatment food intake (g) 25.460.6 20.260.9
Post-treatment body weight (g) 320.567.0 338.967.5
Glucose (mg/dL) 131.362.3 127.764.7
NEFA (mmol/L) 0.4460.06 0.3260.02
TG (mg/dL) 98.5614.3 87.766.7
Lipid WAT (mg/g tissue) 270.9637.3 302.0636.5
Liver TG (mg/g tissue) 8.761.2 8.760.4
Sc treated SD rats
Glucose (mg/dL) 187.1615.9 203.466.8
NEFA (mmol/L) 0.1260.06 0.3160.05*
TG (mg/dL) 86.6630.6 119.3639.8
Values represent mean 6 SEM of n=7–10 rats per group.
*P,0.05 in comparison to control rats, using Student’s t test.
doi:10.1371/journal.pone.0034002.t001
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1.77 mM), followed by centrifugation (3,000 g, 10 min) and
discarding of the aqueous phase. A defined volume was then
transferred into pre-weighted glass tubes and evaporated to
dryness with N2. Lipid content was determined by weighing the
tubes. For the determination of TG content [34], weighed
quantities of frozen tissue (<100 mg) were powdered under liquid
N2 and extracted overnight at 4uC in 6 ml chloroform/methanol
(2:1 vol/vol). Phase separation was obtained after addition of 1 ml
H2SO4 (1 M) and centrifugation (200 g, 10 min). The upper phase
was discarded and the lower phase washed by a further addition of
1m lH 2SO4. Phospholipids were then removed by adding silicic
acid previously activated by heating (150uC, 2 h) and centrifuga-
tion (200 g, 10 min). Two ml of the lower organic phase were then
removed and evaporated under N2. The resulting pellet was
suspended in 200 ml assay buffer (Tris 0.4 M, NaCl 0.2 M, EDTA
10 mM, bovine serum albumin 10 mg/ml, 1% Triton X-100,
pH 8.4), and triglyceride content was determined by colorimetric
enzymatic analysis, as above.
Tissue processing and real-time RT-PCR
Total RNAs were extracted from frozen tissue using a single-step
extraction with Trizol reagent (Sigma-Aldrich, Buchs, Switzerland).
RNA integrity was assessed by electrophoresis on a 1% agarose gel,
and concentration was determined by spectrophotometry. A
quantity of 2.5 mg of total RNAs was used for RT with random
hexamers (Microsynth, Geneva, Switzerland), dNTPs (Promega
Corporation, Madisson, WI, USA), RNasin as an RNase inhibitor
(Promega Corporation), and the M-MLV-RT enzyme kit (Invitro-
gen, Basel, Switzerland). Amplification was either performed from
64 ng cDNA (2 ml of RT), using the SYBR green I DNA Master kit
(Roche Diagnostics, Mannheim, Germany), according to the
LightCycler
TM standard protocol (Roche Molecular Biochemicals,
Basel, Switzerland), or from 12.5 ng cDNA (0.4 ml of RT) using the
SYBRH green PCR Master Mix (Applied Biosystems, Warrington,
UK) on an ABI7500 machine (Applied Biosystems, Foster City,
CA). According to the system used to measure mRNA expression,
primers were either designed with the Primer3 and PrimerExpress
software (Applied Biosystems) (Table S1) and synthesized by
Microsynth (Balgach, Switzerland), Eurogentec (Seraing, Belgium),
or provided by Applied Biosystems. Primers were used at a final
concentration of 200 to 500 nM. Results were normalized to
expression levels of tissue-specific housekeeping genes: ribosomal
protein S29 (RPS29) (white adipose tissue), b-actin (liver, white
adipose tissue), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), cyclophilin A (liver, white and brown adipose tissue)
and 36B4 (hypothalamus).
Figure 2. mRNA and protein expression of different markers of GC and lipid metabolism in Wistar rats. Effect of central (icv)
dexamethasone infusion for 3 days in epididymal (eWAT) and inguinal (iWAT) white adipose tissue. A and C) Results are expressed as percent of
relative mRNA expression compared to that obtained in control rats (100%). The analysis was performed in duplicate and the results were normalized
with RPS29 expression. Mean 6 SEM of n=7 rats per group. *P,0.05 compared to vehicle-infused control rats (Student’s t test). B and D)
Representative Western blots of 11b-HSD1 (n=4–5 per group). Quantification was performed using the ChemiDoc
TM XRS and the Quantity One
TM
software.
doi:10.1371/journal.pone.0034002.g002
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Frozen tissues were mechanically homogenized in ice-cold
RIPA buffer (100 mM Tris, 2% NP40, 0.2% SDS, 0.3 M NaCl
and 1% sodium deoxycholate, pH 7.5) containing protease
inhibitors (Complete Mini, Roche Diagnostics). Proteins were
separated by SDS-10% polyacrylamide gel electrophoresis. After a
blocking period (milk 5% TBS tween 0.1%, 1 h), blots obtained
after transfer on nitrocellulose membranes were incubated with
purified home-made anti-PEPCK [35], anti-11b-HSD1 (Chemi-
con International Inc., Billerica, MA), anti-C/EBPa, anti-C/
EBPb (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), anti-C/
EBPb phosphorylated on ser
105 (P-C/EBPb) (Cell Signaling
Technology, Inc., Beverly, MA) and anti-actin (Chemicon
International Inc.) antibodies overnight at 4uC. Antibodies against
11b-HSD1 and PEPCK were kindly provided by Dr. Karen E.
Chapman (Queen’s Medical Research Institute, Edinburgh, UK)
and Dr. Ildiko Szanto (Centre Me ´dical Universitaire, Geneva,
Switzerland), respectively. Detection was performed using horse-
radish peroxidase-conjugated secondary antibodies (BIO-RAD
Laboratories, Hercules, CA) and an enhanced chemiluminescence
(ECL) detection system (Amersham Biosciences). The results were
then quantified using the ChemiDoc
TM XRS from BIO-RAD and
the Quantity One
TM software.
Statistical analyses
Results are expressed as means 6 SEM. The Levene test was
used to check for the equality of variance among groups (SPSS
Inc., Chicago, IL). To assess the effects of treatment, groups’
comparison was performed using parametric (Student’s t test), and
non-parametric (Mann-Whitney test) tests when normality and
equal variance tests failed. Effect of time was analyzed using one-
way repeated measures ANOVA (Student-Newman-Keuls). Lin-
ear regression models were used to predict correlations between
expression levels of enzymes, using values of the control and the
treated groups. Statistical significance was established at P,0.05.
Results
Stimulation of 11b-HSD1 expression and lipogenesis in
Wistar rats after icv dexamethasone infusion
We first tested the effect of intracerebroventricular (icv) infusion
of dexamethasone in Wistar rats, a strain known for its propensity
Figure 3. Food intake, body weight gain, plasma corticosterone, insulin and leptin levels, as well as metabolic parameters and
locomotor activity of SD rats. Effects of central (icv) dexamethasone infusion for 2 days. A) Results are expressed as food ingested (in grams) each
day of icv infusion. B) Results represent body weight gain (in grams) measured after 1 and 2 days of icv infusion. C) Plasma levels of corticosterone,
insulin and leptin. D) Body composition (% of fat and lean mass) obtained using EchoMRI700
TM. E) Weight (g/100 g of BW) of inguinal (iWAT),
epididymal (eWAT), mesenteric (mWAT) and perirenal (prWAT) white adipose tissue and brown adipose tissue (BAT). F) Results are expressed as
percent of relative mRNA expression compared to that obtained in control rats (100%) and normalized with cyclophilin A expression. Mean 6 SEM of
n=6–8 rats per group. G) Food intake, respiratory quotient (RER), total activity, VO2 and heat (H) production measured using indirect calorimetry
(LabMaster). Values are mean 6 SE of 5 animals per group.
{P,0.05 compared to day 1, using one-way repeated measures ANOVA (Student-
Newman-Keuls test). *P,0.05 compared to vehicle-infused control rats (Student’s t test).
doi:10.1371/journal.pone.0034002.g003
11b-HSD1 Expression in White Adipose Tissue
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e34002and homogeneity to develop age-dependent obesity [36]. No
significant modification of daily food intake was observed in
treated animals (Fig. 1A). Only cumulative food intake over the 3
days of the experiment was increased (62.662.0 vs. 69.361.5 g in
control and dexamethasone-treated rats, respectively, P=0.019).
Body weight gain was also significantly enhanced (day 2: P=0.007
and day 3: P,0.001) (Fig. 1B). As expected, corticosteronemia was
markedly reduced in dexamethasone-treated animals (P=0.001)
(Fig. 1C), while leptinemia increased (P=0.035) (Fig. 1E). As
shown in Fig. 1D and Table 1, plasma insulin, glucose, NEFA and
TG concentrations were unaltered by central dexamethasone
infusion. Measurements of plasma dexamethasone levels at the
end of the experiment revealed a low concentration of the drug
(2.9460.68 ng/ml), far below normal plasma corticosterone levels
(Fig. 1C), indicating the absence of leakage from the cerebrospinal
fluid into the peripheral circulation.
In epididymal white adipose tissue (eWAT), chosen to represent
an intraperitoneal fat pad, neither the mRNA (Fig. 2A), nor the
protein (Fig. 2B) expression of 11b-HSD1 was modified by
dexamethasone treatment. However, the expression of lipogenic
enzymes, such as lipoprotein lipase (LPL), acetylCoA carboxylase
(ACC) and fatty acid synthase (FAS), as well as that of resistin were
significantly increased. In the inguinal WAT (iWAT), chosen to
represent a subcutaneous fat pad, a marked increase in 11b-HSD1
mRNA (4-fold) (P=0.034) (Fig. 2C), with no change in protein
expression (Fig. 2D) was observed in the dexamethasone-treated
group. This was accompanied by elevated expression of H6PDH
(P=0.037), FAS (P=0.008) and resistin (P=0.045) (Fig. 2C). Of
note, mRNA expression of enzymes implicated in lipolysis and lipid
utilization, such as hormone sensitive lipase (HSL) and carnitine
palmitoyltransferase type 1 (CPT1), was significantly decreased
(P=0.017 and P=0.004, respectively). In both the intraperitoneal
and the subcutaneous fat depots, the expression of 11b-HSD2 and
GR was unaffected by central dexamethasone infusion.
Regarding the discrepancy between dexamethasone-induced
11b-HSD1 expression in intraperitoneal and subcutaneous
adipose tissue, it is interesting to note that the gene was
substantially more expressed in the former than in the latter fat
depot (Ct of 23.8660.52 and 32.3462.31, respectively; P=0.011).
In the liver, the mRNA expression of 11b-HSD1 and H6PDH, as
well as the mRNA and protein expression of PEPCK, the key enzyme
forgluconeogenesis,were unaltered by the treatment(data notshown).
Stimulation of 11b-HSD1 expression and lipogenesis in
SD rats after icv dexamethasone infusion
The effects of icv dexamethasone infusion were then studied in
SD rats, a strain described as having different susceptibility to
Figure 4. mRNA and protein expression of different markers of GC and lipid metabolism in SD rats. Effects of central (icv)
dexamethasone infusion for 2 days in epididymal (eWAT) and inguinal (iWAT) adipose tissue. A and C) Results are expressed as percent of relative
mRNA expression compared to that obtained in control rats (100%). The analysis was performed in duplicate and the results are normalized with
RPS29 expression. Mean 6 SEM of n=7–8 rats per group. *P,0.05 compared to vehicle-infused control rats (Student’s t test). B and D) Representative
Western blots of 11b-HSD1 (n=6–7 per group). Quantification was performed using the ChemiDoc
TM XRS and the Quantity One
TM software. *P,0.05
compared to vehicle-infused control rats (Student’s t test).
doi:10.1371/journal.pone.0034002.g004
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The treatment induced a significant increase in food intake and
body weight gain compared to controls (Figs. 3A and 3B). The
expected decrease in corticosteronemia (P,0.001) was accompa-
nied by elevated basal plasma insulin (P=0.047) and leptin
(P=0.046) levels (Fig. 3C). These results are in line with and
extend previously published data showing that icv infusion of GCs
results in the induction of increased body weight gain and insulin
resistance in SD rats [25]. Plasma glucose, NEFA and TG
concentrations, as well as lipid content in inguinal WAT and TG
content in the liver were, however, not significantly modified by
this short period of dexamethasone treatment (Table 1).
To evaluate the qualitative nature of the dexamethasone-
induced increase in body weight, another experiment was
performed to measure body composition using an EchoMRI
analyser. A tendency toward an increase in percent fat mass was
observed in dexamethasone-treated animals (Fig. 3D). At the end
of these experiments and following sacrifice, iWAT, eWAT,
perirenal (prWAT) and mesenteric (mWAT) adipose tissue depots
were dissected, and weighted. Both the subcutaneous iWAT and
the intraperitoneal (eWAT, mWAT) fat pads were significantly
increased by the dexamethasone treatment (Fig. 3E).
Various metabolic parameters and locomotor activity were also
determined. Online food intake measurements allowed to observe
that the increased food intake of dexamethasone-treated rats was
due to increased food consumption during the diurnal period
(Fig. 3G). No modification of the RER was observed during the
night. However, the diurnal RER tended to be higher in
dexamethasone-treated than in control animals, suggesting
decreased lipid mobilization as an energy source. No differences
in physical activity, neither ambulatory nor fine, were noticed
between the two groups. Recording of VO2 and heat (H)
production revealed lower values in dexamethasone-treated rats
compared to controls, reflecting lower energy expenditure and a
trend towards decreased thermogenesis (Fig. 3G). Such a trend
was consistent with the observation of decreased mRNA
expression of the two uncoupling proteins, UCP1 (P=0.015)
and UCP3 (P=0.017) in brown adipose tissue (Fig. 3F), as
previously described [11].
Confirming the already described involvement of NPY neurons
in the mediation of the central dexamethasone effects [24], mRNA
expression levels of NPY were 2.4 fold-increased in hypothalami of
treated animals (100.0665.3 and 241 .1673.2% for control and
treated animals, respectively, P=0.044).
In eWAT, mRNA expression of 11b-HSD1 was not modified
by dexamethasone treatment (Fig. 4A), but protein expression was
significantly increased (P=0.003) (Fig. 4B). In iWAT, 11b-HSD1
mRNA expression tended to increase (Fig. 4C), with no change in
protein levels (Fig. 4D). H6PDH, FAS and resistin expression was
also significantly enhanced by dexamethasone (P=0.026,
P=0.048, and P=0.014, respectively), H6PDH being strongly
correlated with 11b-HSD1 expression (r
2=0.507, P=0.004)
(Fig. 4C). As observed in Wistar rats, 11b-HSD1 was substantially
more expressed in eWAT than in iWAT (Ct of 21.9960.30 and
24.6260.39, respectively; P=0.0001). In both these depots,
Figure 5. mRNA and protein expression of markers of GC action and gluconeogenesis in the liver of SD rats. Effects of central (icv)
dexamethasone infusion for 2 days. A) Results are expressed as percent of relative mRNA expression compared to that obtained in control rats
(100%). The analysis was performed in duplicate and the results were normalized with GAPDH expression. Mean 6 SEM of n=7–8 rats per group.
*P,0.05 compared to vehicle-infused control rats (Student’s t test). B and C) Representative Western blots of 11b-HSD1 and PEPCK (n=4–5 per
group). Quantification was performed using the ChemiDoc
TM XRS and the Quantity One
TM software.
doi:10.1371/journal.pone.0034002.g005
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Partial compensatory mechanism in the liver of SD rats
after icv dexamethasone infusion
In contrast to what was observed in Wistar rats, a significant
decrease in 11b-HSD1 mRNA expression was observed in the
liver of dexamethasone-treated SD rats (P=0.007), with a similar
expression for H6PDH (Fig. 5A), both parameters being highly
correlated (r
2=0.692, P=0.001). 11b-HSD1 protein expression
also tended to decrease (Fig. 5B). In addition, PEPCK mRNA
expression was reduced in dexamethasone-treated rats (P=0.016)
(Fig. 5A) and there was a significant correlation between PEPCK
and 11b-HSD1 expression in this tissue (r
2=0.353, P=0.032).
PEPCK protein levels were, however, unaltered by central
dexamethasone infusion (Fig. 5C).
Implication of C/EBPa and C/EBPb after icv
dexamethasone infusion
Recent evidence suggests that the expression ratio of the
transcription factors CCAAT enhancer binding protein (C/EBP)a
to C/EBPb might be important for the control of 11b-HSD1
expression [39,40,41,42]. The expression of these two transcrip-
tion factors was therefore characterized in iWAT and the liver of
control and dexamethasone-treated SD rats. First, and as depicted
in Fig. 6A, a two-fold increase in C/EBPa mRNA expression was
Figure 6. C/EBPa, C/EBPb mRNA and protein expression in iWAT (A) and in the liver (C) of SD rats. Effects of central (icv) dexamethasone
infusion for 2 days. A and C) Results are expressed as percent of relative mRNA expression compared to that obtained in control rats (100%). The
analysis was performed in duplicate and the results were normalized with RPS29, b-actin and GAPDH expression. Mean 6 SEM of n=7–8 rats per
group. B) Representative Western blots of C/EBPa, C/EBPb and phosphorylated C/EBPb-ser
105 (n=5 per group). Quantification was performed using
the ChemiDoc
TM XRS and the Quantity One
TM software. *P,0.05 compared to vehicle-infused control rats (Student’s t test).
doi:10.1371/journal.pone.0034002.g006
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(P=0.043), while C/EBPb mRNA expression was unaltered by
the treatment. This C/EBPa mRNA increase was highly
correlated with the expression of resistin (r
2=0.905, P=0.001).
When calculating the gene expression ratio of C/EBPa to C/
EBPb, an almost three-fold, although not significant increase was
obtained in dexamethasone-treated animals (Fig. 6A). With regard
to protein expression measured by Western blot analysis, a though
1.6 fold increase in C/EBPa was observed in the dexamethasone-
treated group (Fig. 6B). In this group, both C/EBPb and P-C/
EBPb expressions similarly increased by 1.86 folds. The resulting
ratio between C/EBPa and C/EBPb was unaltered by dexa-
methasone infusion at the protein level.
With regard to the liver, central dexamethasone administration
induced a decreased C/EBPb mRNA expression (P=0.035), with
no change in C/EBPa (Fig. 6C). The ratios of C/EBPa to C/
EBPb mRNA levels was comparable in the livers of both groups.
Effect of peripheral dexamethasone infusion in SD rats
Finally, in order to investigate the potential occurrence of
dexamethasone leakage from the cerebrospinal fluid into the
peripheral circulation, we infused 5 mg/day of dexamethasone
subcutaneously (sc) during 2 days in SD rats. This treatment led to
significant decreases in both daily food intake and body weight
gain, compared with control rats receiving vehicle (Figs. 7A and
7B). Plasma corticosterone, leptin, glucose and TG levels were
unaltered, while plasma insulin (P=0.009) and NEFA (P=0.024)
concentrations were elevated (Figs. 7C–E and Table 1). The fact
that, under these experimental conditions, dexamethasone infu-
sion failed to decrease corticosterone levels suggested that the
synthetic GC did not get into the brain. This was examined by
determining the hypothalamic CRH mRNA expression, which
was indeed unaltered by the treatment (100.0614.9 and
90.0620.4% for control and dexamethasone-treated rats, respec-
tively, NS).
Figure 7. Food intake, body weight gain, corticosterone, insulin, leptin levels, 11b-HSD1 and resistin mRNA expression in SD rats.
Effects of peripheral (sc) dexamethasone infusion for 3 days. A) Results are expressed as food ingested (in grams) each day of peripheral infusion. B)
Results represent body weight gain (in grams) measured after 2 days of treatment. C to E) Plasma levels of corticosterone, insulin and leptin. F and G)
Results are expressed as percent of relative mRNA expression compared to that obtained in control rats (100%). The analysis was performed in
duplicate and the results were normalized with RPS29 expression. Mean 6 SEM of n=8–9 rats per group. *P,0.05 compared to vehicle-infused
control rats (Student’s t test).
doi:10.1371/journal.pone.0034002.g007
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(P=0.024) (Fig. 7F) and resistin (P=0.028) (Fig. 7G) mRNA
expression was lowered in iWAT of dexamethasone-treated rats.
In the liver, neither the mRNA expression of 11b-HSD1, H6PDH,
nor the mRNA or protein expression levels of PEPCK was
modified. Finally, C/EBPa and C/EBPb mRNA expression in
iWAT or the liver was unaltered by this dose of peripheral
dexamethasone administration (data not shown).
Discussion
The present study aimed at determining the influence of short-
term central glucocorticoid administration on local 11b-HSD
expression in adipose tissue and in the liver to evaluate whether
metabolic consequences of such a treatment, i.e. increased body
weight gain and specific skeletal muscle insulin resistance [24,25]
may involve tissue-specific alterations.
As expected, centrally dexamethasone-infused rats displayed
hypocorticosteronemia as a result of forcing the feedback
inhibition of the HPA axis. The treatment also rapidly induced
an increase in body weight gain due to increased food
consumption during the diurnal period. Plasma leptin levels were
significantly elevated, as was the mRNA expression of lipogenic
enzymes such as FAS, suggesting the occurrence of increased lipid
storage in subcutaneous and intraperitoneal white adipose tissue
depots. Moreover, indirect calorimetry revealed a decreased rate
of lipid oxidation in dexamethasone-treated rats during the diurnal
period, together with indices of decreased energy expenditure and
thermogenesis. In the Wistar strain exhibiting a high propensity to
develop age-dependent obesity [36], the dexamethasone-induced
increase in FAS expression was also accompanied by decreased
expression of enzymes involved in lipolysis and lipid utilization.
Altogether, these results confirm and extend our previous
observations suggesting that short-term icv dexamethasone
infusion in rats reproduces the initial metabolic defects occurring
in obesity.
Analyzing the mRNA expression of 11b-HSD1, a differential
regulation pattern was observed depending on the tissue and the
strain. In obesity-prone Wistar rats [36], there was a marked
dexamethasone-induced increase in 11b-HSD1 mRNA in inguinal
white adipose tissue (iWAT). That was less obvious in SD animals
known to be more heterogeneous in the face of diet-induced
obesity [37,38]. However in SD rats, a mild increase in 11b-HSD1
protein level was observed in the epididymal depot (eWAT). In
addition to such a strain difference, it is also conceivable that
regulation of 11b-HSD1 is transcriptional or translational, partly
depending on its gene expression level. This is suggested by the
observation that, under basal conditions, the expression of the
enzyme was higher in intraperitoneal (eWAT) than in subcutane-
ous (iWAT) depots. It could thus be proposed that transcriptional
11b-HSD1 regulation is occurring when the enzyme is poorly
expressed, while translational modulation occurs under high
expression conditions.
Interestingly, the expression profiles of 11b-HSD1 and
H6PDH, an enzyme determining the reductase activity of 11b-
HSD1 [43,44,45], were similar and correlated within a given tissue
and strain. As a whole, the results suggest enhanced 11b-HSD1
activity and activation of intracellular GCs in subcutaneous
adipose depots of Wistar and SD rats. It should however be
pointed out that these changes are only relevant if the plasma
levels of 11-dehydrocorticosterone, the substrate for 11b-HSD1
enzymatic activity, are not decreased by dexamethasone infusion.
To examine this issue, preliminary data were obtained by
measuring both plasma corticosterone and 11-dehydrocorticoster-
one using LC-MSMS. They showed that the plasma concentra-
tions of both compounds were unaffected by the dexamethasone
treatment. Although these data need to be confirmed, they suggest
that the availability of the substrate for 11b-HSD1 is not impaired
by dexamethasone infusion.
Increased 11b-HSD1 activity and activation of adipose tissue
GC production could be of importance, given the fact that these
hormones have clear effects in adipose tissue, where they markedly
potentiate the insulin effect on triglyceride uptake via the
stimulation of lipoprotein lipase activity [46], while also promoting
adipocyte differentiation [47]. Moreover, the observation that
mice with adipose tissue 11b-HSD1 overexpression develop a
visceral obesity syndrome with accompanying metabolic defects
[19,20] suggests that increased adipose tissue 11b-HSD1 expres-
sion might play a role in the development of obesity. Along this
line, it should be noted that increased adipose tissue 11b-HSD1
expression was also observed in rodent models of genetic obesity
[48], as well as in high fat fed mice [49].
Knowing that C/EBPs seem to play a key role in the activation
of 11b-HSD1 and lipid storage-related genes in adipocytes
[39,42,50,51], the expression of C/EBPa and C/EBPb, was
determined. C/EBPa was indeed described as a potent activator of
11b-HSD1 and resistin [52], while C/EBPb was described as a
key mediator of 11b-HSD1 expression [41]. Accordingly, we
observed that C/EBPa and resistin were overexpressed in inguinal
adipose tissue of dexamethasone-treated SD rats with a strong
correlation between both parameters. This is of importance as
resistin may represent one of the mechanisms underlying the
occurrence of muscle insulin resistance observed in response to
central GC administration [24,53,54].
The situation was quite different in the liver, where we observed
decreased mRNA expression of 11b-HSD1, C/EBPb and PEPCK
in dexamethasone-treated SD rats, with a trend toward a decrease
in 11b-HSD1 and no change in PEPCK protein level. The liver is
another tissue in which GCs may affect glucose metabolism. Of
note, liver-specific overexpression of 11b-HSD1 resulted in insulin
resistance and hypertension, but, in contrast to adipose tissue
overexpression, it did not promote obesity [55]. In accordance,
antisense-mediated inhibition of 11b-HSD1 in mice fed a
Western-type diet resulted in improved plasma and hepatic lipid
levels and reduced hepatic lipogenesis [56]. Decreased hepatic but
enhanced adipose tissue 11b-HSD1 expression and activity were
measured in genetically obese Zucker rats, ob/ob mice [5,6,20,57],
as well as in obese humans [16]. This might represent the
establishment of a partial compensatory mechanism aimed at
resisting hyperglycemia [10] by increasing local insulin sensitivity
[58]. Interestingly, such an adaptation was only observed in the
most obesity resistant strain, the SD rat after 2 days of
dexamethasone treatment. Of note is the observation that a
similar mechanism has been described in Wistar rats after 3 weeks
of high fat feeding [8]. It is therefore possible that the
dexamethasone treatment used in the present study was not long
enough to induce this pathway in Wistar rats.
Regarding the mechanisms that could be implicated, one of the
first questions posed is whether these changes are centrally elicited
or whether they result from leakage of dexamethasone from the
ventricular system into the peripheral circulation. In contrast to
the icv treatment, peripheral dexamethasone treatment lowered
food intake and body weight gain, but resulted in hyperinsulinemia
and elevated plasma NEFA levels. The latter observation is in line
with the lipolysis-inducing effects of GCs. These data favor the
view that the icv dexamethasone-induced effects observed in our
study are centrally elicited. This is also in keeping with data
showing that central dexamethasone infusion decreases the
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a peptide known to promote the development of hyperphagia,
vagus nerve-mediated basal insulin output and fat storage upon
central infusion in normal rats [25,59]. Finally, an involvement of
insulin and corticosterone in the 11b-HSD1 changes observed
could be considered, given their respective transcriptional
inhibitory and stimulatory effects described in vitro
[60,61,62,63,64]. However, in the present in vivo study, these
hormones are unlikely to play a role, given that the changes in
expression are tissue-specific and that the prevailing low levels of
circulating corticosterone should allow unopposed inhibitory
insulin effects on 11b-HSD1, which is not observed in adipose
tissue.
Taken together, these results show that acute central glucocor-
ticoid administration causes differential effects on local GC
activation. We propose that in this acute model, the GC-
dependent metabolic disturbances first appear in adipose tissue
overexpressing resistin and in skeletal muscles exhibiting marked
insulin resistance [24]. The concomitant decreased GC activation
in the liver would initially limit the metabolic disturbances
accompanying the development of increased body weight. The
particular importance of GC activation in adipose tissue for the
development of metabolic dysfunctions is further strengthened by
the observations that administration of specific 11b-HSD1
inhibitors resulted in significant improvement of glucose and lipid
profiles, together with a weight reduction, provided that 11b-
HSD1 activity was decreased in adipose tissue, rather than in the
liver [65]. The precise mechanisms by which GCs affect peripheral
metabolism by exerting a central action need to be further
elucidated.
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